BN104
Acute Myeloid Leukemia With 11q23 Abnormalities
Explore 25 assets in Acute Myeloid Leukemia With 11q23 Abnormalities →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06052813CT.gov A Study of BN104 in the Treatment of Acute Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With 11q23 Abnormalities
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| BN104 (this asset) | Institut de Recherches Internationales Servier (I.R.I.S.) | P1/2 | CCC · 48 |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P2 | BBB |
| Cytarabine | Alice Mims | P3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
| Fludarabine | M.D. Anderson Cancer Center | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BBB |
| Nivestim | M.D. Anderson Cancer Center | P3 | BBB |
+42 more in the Acute Myeloid Leukemia With 11q23 Abnormalities cohort
Other indications for BN104
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Leukemia | — | P1/2 | CCC · 48 |
| Adult Acute Lymphoblastic Leukemia | — | P1/2 | CC · 47 |
| Acute Myeloid Leukemia With Mutated NPM1 | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. BN104 in Acute Myeloid Leukemia With 11q23 Abnormalities. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bn104-acute-myeloid-leukemia-with-11q23-abnormalities
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →